Surgical Resection or Radiofrequency Ablation for Small Hepatocellular Carcinoma.

"Conflict of Interest Statement Yoshikuni Kawaguchi: lecture fees from Olympus, Conmed, Johnson and Johnson, KAKEN, Otsuka, JSS, and Chugai. Ryosuke Tateishi: lecture fees from Chugai, Daiichi Sankyo, Eisai, GE Health Care, Gilead; advisory roles with AstraZeneca and Shionogi, Medtronic, MSD, Otsuka, Sumitomo Dainippon Pharma, Kowa Company, Takeda, Ono, and Shionogi. Norihiro Kokudo: lecture fees from AstraZeneca and Eisai. Kiyoshi Hasegawa: lecture fees from EA Pharma, Finefield, MSD, Astellas, AbbVie, Alfresa, Incyte Biosciences, Viatris, Eisai, KAKEN, Tsumura, Phase 1 Inc., Medical Review, Yakult, Medtronic, Johnson & Johnson, DAIICHI SANKYO, Takeda, Chugai, TERUMO, Eli Lilly, NIHON PHARMACEUTICAL, Bayer, Baxter, FUJIFILM Healthcare Corporation, and Mylan EPD; research funding from Chugai, Otsuka, Takeda, Taiho, Yakult, Eisai, Bayer Yakuhin, Shimazu, Nipro, KAKEN, Tsumura, Eli Lilly, MSD, Astellas, and Mochida. Norihiro Kokudo is Associate Editors of Liver Cancer. Kiyoshi Hasegawa is an Editorial Board Member of Liver Cancer. None of the other authors have potential conflicts of interest to declare."

"This work was not supported by any funds."